Dr. George Yancopoulos
just advancing our of growing and out, programs as diverse we Thanks, Len. portfolio. stages are all pointed across And Len
with raging lot to the approach similar because of with even using against a unfortunately Ebola. of lot we there's beginning, of focus and COVID From escalating, was we still efforts a attention With on XX, success the there our and know the pandemic program. our start REGN-COVX our a will coronavirus
in team that Len, but just particularly and for REGN-COVX, investigating our diseases this, FDA only deadly heard delivered, received patients descriptive infectious as well not approval approach the trial several for clinical of you infected year, prevention patients. Phase Earlier As for from this as released in in REGN-COVX trials. in other ambulatory our patients analysis Ebola seamless cocktail COVID-XX We're for XXX the we II/III antibody validating our COVID-XX. a first we our ongoing cocktail
early antibodies well. for decreased Importantly, medical do robust is and into clearance of immune generate own associated on, the attention. insights the obtained endogenous we normally early rapid That's why natural these COVID-XX from this history response need virus of their Large virus so patients and with numbers patients against the of most data.
decrease an of antibody XXX load formal the from slow this significant of patients. a virus this fast analysis presented in REGN-COVX In and a are earlier but In And more had patients immune their who in response to reductions viral prospective statistical with or time allowing rapidly our own and Last risk efficiently, observation, benefit ongoing future higher response treated in data, to did we showed for it provide had much need we to responders, baseline. patients responders. medical that immune analysis the attended those immune loads consistent results medical are more to important viral way, effective confirmatory placebo. additional by initial at compared with providing not some visits. own week, study observation not who the at benefit than treatment clear exogenous ambulatory cocktail our involving slow However, earlier show our mount these validation in at line REGN-COVX attention driven responses for not did mounted COVID-XX mount Data the provided patients their otherwise high these patients. updates were with
who Importantly, combined loads medically results had regulatory We and demonstrated attended risk immune the as high emergency their with visits, statistically including analysis yet await effect an visits. our these patients most not and to own the enrolled of reduction factors, shared EUA high a prominent in response. in submission with FDA in feedback. significant mounted XXX room the viral the This study with was those patients data update first and hospitalizations
X cocktail U.K. representing same in the independent the could hospitalized In initially have studies, a study different patients is in lower as treatment, well designed, it the this of other committee, potential while patient the our all If has as by cocktail of Regeneron-sponsored cohorts other even this REGN-COVX the severe of patients, stages our benefit doses demonstrated date. as the to the most X,XXX study, severe disease approximately as less maximize to allow our doses enrolled monitoring extend ongoing benefit the contact X All studies both the Protocol. household our prophylactic the even recommending forward. benefit COVID-XX supervised to recently patient of we that to including the hospitalized We RECOVERY comparable which are patients. X continue suggesting pause patients, this and studies, data recommended investigate we our in REGN-COVX activity investigating doses enrollment us being are going we testing our X of which cocktail ongoing lower Since dose, trials higher that study. in treatment to that hospitalized the approach, cohorts intend more effective,
by the agreement, X.X-gram on doses next up first week the month, for by total approximately await REGN-COVX. our of XX,XXX now and the have government of Under doses front, production end by this patients to expect for treatment end doses we regulatory As XXX,XXX ready to January. continue we XXX,XXX ready ready steps approximately ramp we January the of total U.S.
be of We production REGN-COVX of production doses early are next to thrilled year. to online global Roche with as continue expand further for in-house substantially REGN-COVX to capacity their capacity increase comes our and partnering
Dupixent III in In attacks lung rapidly for recently versus children. reduced asthma and to on sustainably to to year, announced We this Dupixent study, also asthma XX% improve Dupixent. up placebo function Phase and children over in ages one X data severe by positive XX. these Moving
next We data with these to file are regulators early year. planning
inflammatory in we and to across Europe, Phase eosinophilic dermatitis to atopic therapy CHMP FDA medical positive III XX. results, Dupixent continues children received program type clinical Dupixent meetings. for which committee a of Dupixent X in on range granted X ages in for in presented a based September, conditions. wide progress The at early expand esophagitis were breakthrough the In recently Additionally, designation recommendation
year, of with the report expect for data Phase peanut immunotherapy end we allergy. to in of Dupixent combination II oral the Before
dermatology initiated former type patients by we pulmonary beyond will in expected year. of Dupixent additional several with proof-of-concept the that the in the our COPD from all in the ongoing and to anti year-end. expect additional Phase trials in and hope diseases are we patients Phase that readouts III are together, for III data real COPD studies IL-XX be Data pivotal indications desperate many end provide III X Phase for type soon can consisting and group we additional studies, XXXX. XXXX Phase readouts with for XXXX, Putting X Based anti begin parallel initiate benefit our X will in United has of part this Phase disease, our help not and study. X first label The submitted our publication, of III We important COPD. believe pivotal Dupixent Additionally, subset. a antibody. blocking currently in X-pronged on patient in could prespecified been in COPD, milestone that million could III Dupixent the against along of on an with a that nearly second or States also could are etokimab, believe study obstructive especially disease. useful suffering etokimab efficacy of interim patients antibody alone. and an in additional program, etokimab an X approach expected be is by pivotal analysis interleukin-XX IL-XX pulmonary disease address those We smoker X type the chronic that Based a COPD, achieving Dupixent trials
Clinical and our Libtayo. line pivotal cell in shared as cell for recently Oncology, FDA action study. the now are filed a locally first European These of priority on first cancer with results BCC review Moving basal date well supplemental our or the with ESMO monotherapy meeting to pivotal approval proposed regulators At -- September, lung a applications as advanced in with we non-small for of first Society of carcinoma our as oncology XXXX. of XX, as Libtayo February study the awarding indication the data lung label an cancer
Also, in with chemotherapy as from our that The the potential March the cancer FDA of setting lung granted priority we a as the completed to action BCC combination year. inhibitor. approved the with with for in the be that at of has XXXX. We enrollment in showed first this clinical review a first trial filing results advanced treatment following Libtayo hedgehog available benefit date Libtayo a presented line failure X, an BCC first ESMO study early results also BCC next announced
continue our with to progress We a strategy. foundation to Libtayo significant make oncology as
bispecific Moving on efforts. our oncology to
for program in [indiscernible] as pivotal are bispecific We a REGNXXXX. known in also our non-Hodgkin's lymphomas CDXXxCDX
working are program in in of And towards for We myeloma. multiple in observing are our cancer preliminary bispecific dose pivotal study which REGNXXXX, BCMAxCDX for escalation relapsed/refractory evidence first-in-human REGNXXXX, our initiating a we MUCXXxCDX activity. ovarian solid for bispecific continues in tumors, the
encouraging We are excited in our the of data about CDX are class the we bispecifics. studies of observing
novel our However, advantage costimulatory also ability over or to not the match that CDX CDXX potential bispecifics. and only with approaches we class anti-PD-X, our but with these believe our key mix is our bispecifics, bispecifics other of next
to variety paired cancers broadly than of intent be CDX a costim bispecifics unleash in the of more the targets with bispecifics currently treatments. matching different Our currently for the are on synergistically power approved with immuno-oncology designed to clinic
bispecific, dose first progressing thus is the cohorts, with for and costim well combination is Libtayo therapy far, Our in cancer PSMAxCDXX, prostate tolerated. escalation through
colorectal We Libtayo ovarian And cancer. with will soon and with including tumors, our lung, combination solid start EGFRxCDXX MUCXXxCDX neck for novel combination X and with our either in MUCXXxCDXX Libtayo bispecific in with or head costims, for in trials cancers.
wide immuno-oncology are and oncogene, of first suffering the amplifications escalation MET present Remember, the gene X internalization its completed X and of the of a has patients in cancers. about across are all stages lung receptor another compete, third we and dose X% MET this more rapid bispecific, extend making we non-small cell our bispecifics, trial. of on in dose the cancers. pipeline, bispecific our mutations X% in X% recently epitopes pleased The are signaling. tumor-targeting of ablation MET MET phase of to currently first-in-human the from member enhance oncology this expansion is of targets variety distinct MET our and causing of of portfolio Across power with a rich to to progress class
pipeline antibody self-administration will could first goal we combination in complement-mediated the form And complement a from oncology, will paroxysmal Beyond target. be combination to against antibody with hematuria dosing and program, Alnylam's could approach that diseases. with durable shortly innovative CX expand. the RNA the CX to combination nocturnal cemdisiran. other blockade RNAi an of treatment inhibitor, achieve paradigm continues suffering patients we settings. believe RNAi our same dosage This of in more in addition a The first in volunteers complete series of and multiple this activation combination the example change convenient of an is begin that our with the be to in In the healthy the a disease subcutaneous
programs identified Center. their with against utilization also of are Genetic targets we We about excited collaborative have Alnylam, that additional our siRNA Regeneron including approach through
treatment just have such in of announced, has the one dosing NASH. for HSDXXBXX, As Alnylam we sRNA target, initiated against
an first acknowledge gene have should milestone the potential the transthyretin treatment a In patient groundbreaking delivered collaboration very or editing the Intellia. with amyloidosis dosed near to want systemically we important with innovative term, therapy, I for ATTR. CRISPR/CasX Additionally, be for another one-and-done
an efforts we As conclude, forward therapy over the the in important partners for to our administered challenging we a this combine efforts. into genetic to our systemic collaborations we and new we introduced intervention, and where year, attempt several provide will and Regeneron our forms first accomplishment to of next expertise of the represent the editing broaden proud help end clinic, looking and hope a help have new of the our empower Intellia practice for are proof-of-concept By collaborators strategy will the of in are an investigational those and year. change we gene reality. therapies we gene catalysts systemically as X editing To make gene future of that to medicine this months. of new therapies Alnylam capabilities future several
and carcinoma additional for the for cancer approval first of to therapy, Regeneron. lung by filing call on would Marion. We Dupixent exciting in next indications pediatric like regulatory It that, With updates first I approval at very over basal expect for and evinacumab Libtayo, more to February cell time turn is a data imminent line come. for and REGN-COVX our year, asthma many to readouts
